α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Distribution of α-Synuclein Aggregation in the Peripheral Tissues

Exosomal transmission of α-synuclein initiates Parkinson's disease-like pathology

Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies

Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

IJMS, Free Full-Text

Stress-induced p53 drives BAG5 cochaperone expression to control α-synuclein aggregation in Parkinson's disease - Figure f6

Cellular models of alpha‐synuclein toxicity and aggregation - Delenclos - 2019 - Journal of Neurochemistry - Wiley Online Library

Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology

α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect

α-synuclein strains that cause distinct pathologies differentially inhibit proteasome

Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review)

Alpha-Synuclein aggregation HTRF kit

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

Alpha Synuclein in Parkinson's Disease Diagnostics

Chemical disaggregation of alpha-synuclein fibrils as a therapy for synucleinopathies